Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
Analytical Biochemistry
|
August 15, 1987
A microtechnique for dialysis of small volume solutions with quantitative recoveries
C M Overall
Journal of Cellular Physiology
|
July 1, 1995
Repression of tissue inhibitor of matrix metalloproteinase expression by all-trans-retinoic acid in rat bone cell populations: comparison with transforming growth factor-beta 1
C M Overall
Matrix (Stuttgart, Germany). Supplement
|
January 1, 1992
Matrix metalloproteinases in periodontal tissue remodelling
J Sodek, C M Overall
British Journal of Cancer
|
March 16, 2006
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
C M Overall, O Kleifeld
The Biochemical Journal
|
December 15, 1988
Identification and characterization of enamel proteinases isolated from developing enamel. Amelogeninolytic serine proteinases are associated with enamel maturation in pig
C M Overall, H Limeback
Journal of Dental Research
|
July 1, 1987
Initial characterization of a neutral metalloproteinase, active on native 3/4-collagen fragments, synthesized by ROS 17/2.8 osteoblastic cells, periodontal fibroblasts, and identified in gingival crevicular fluid
C M Overall, J Sodek
The Journal of Biological Chemistry
|
December 5, 1990
Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases
C M Overall, J Sodek
The Journal of Biological Chemistry
|
March 14, 1997
The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components
U M Wallon, C M Overall
Current Pharmaceutical Design
|
February 23, 2007
Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry
G S Butler, C M Overall
Journal (Canadian Dental Association)
|
May 1, 1995
Papillon-Lefèvre syndrome associated early onset periodontitis: a review and case study
D French, H Scott, C M Overall
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
Analytical Biochemistry
|
August 15, 1987
A microtechnique for dialysis of small volume solutions with quantitative recoveries
C M Overall
Journal of Cellular Physiology
|
July 1, 1995
Repression of tissue inhibitor of matrix metalloproteinase expression by all-trans-retinoic acid in rat bone cell populations: comparison with transforming growth factor-beta 1
C M Overall
Matrix (Stuttgart, Germany). Supplement
|
January 1, 1992
Matrix metalloproteinases in periodontal tissue remodelling
J Sodek, C M Overall
British Journal of Cancer
|
March 16, 2006
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
C M Overall, O Kleifeld
The Biochemical Journal
|
December 15, 1988
Identification and characterization of enamel proteinases isolated from developing enamel. Amelogeninolytic serine proteinases are associated with enamel maturation in pig
C M Overall, H Limeback
Journal of Dental Research
|
July 1, 1987
Initial characterization of a neutral metalloproteinase, active on native 3/4-collagen fragments, synthesized by ROS 17/2.8 osteoblastic cells, periodontal fibroblasts, and identified in gingival crevicular fluid
C M Overall, J Sodek
The Journal of Biological Chemistry
|
December 5, 1990
Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases
C M Overall, J Sodek
The Journal of Biological Chemistry
|
March 14, 1997
The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components
U M Wallon, C M Overall
Current Pharmaceutical Design
|
February 23, 2007
Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry
G S Butler, C M Overall
Journal (Canadian Dental Association)
|
May 1, 1995
Papillon-Lefèvre syndrome associated early onset periodontitis: a review and case study
D French, H Scott, C M Overall
Page
of 6